Phase 1 Results for Imaging Agent Cu-61 NuriPro Shows Promise for Future Theranostic Option Cu-67

June 25, 2025/in Clinical Trial, Metastatic, Phase 1/by Max

At the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, a promising phase I clinical trial results were presented for Cu-61 NuriPro, a next-generation PET imaging agent specifically designed for patients with PSMA-positive metastatic prostate cancer. This agent targets prostate-specific membrane antigen (PSMA), a protein commonly overexpressed in prostate cancer cells, making […]